Frank W.G. Leebeek, MD, PhD

Professor and Head of Department of Hematology
Erasmus MC, University Medical Center Rotterdam, The Netherlands

Frank Leebeek obtained his medical degree from the Erasmus University in Rotterdam, the Netherlands in 1990. His earned his PhD degree in clinical studies on fibrinolysis inhibitors synthesized by the liver at the Erasmus University in Rotterdam. He subsequently worked as a post-doctoral fellow for 2 years at the University of North Carolina at Chapel Hill, USA. He was trained as a haematologist at the Erasmus University Medical Center in Rotterdam, where he became a staff member and was appointed full professor in 2009. He is chair of the Department of Haematology since 2017. He is coordinating a research team on haemostasis and thrombosis with several research topics, mainly inherited bleeding disorders such as von Willebrand disease and haemophilia, including gene therapy studies. He is the principal investigator of the Willebrand in the Netherlands (WiN) study.
He has been secretary of the Dutch Society of Thrombosis and Haemostasis, chairman of the Dutch Hemophilia Doctor’s Organisation, and is currently a board member of the Dutch Society of Haematology and the European Hematology Association. He has been co-chair of the Scientific and Standardization Committee on von Willebrand Factor of the International Society on Thrombosis and Haemostasis. Dr Leebeek has (co-)authored over 400 scientific publications listed on PubMed, 20 book chapters and contributed to national and international treatment guidelines on haemophilia, von Willebrand’s disease and venous thrombosis.

Presentation(s):

• OC 09.3 - Differential fate of Von Willebrand factor and Von Willebrand factor propeptide following release from platelet alpha-granules

  Saturday, July 9, 2022
  1:30 PM – 1:45 PM

• SS 07.2 - Challenging the System: Current Models of Care in Haemophilia

  Sunday, July 10, 2022
  1:25 PM – 1:40 PM

• SS 07.4 - Question & Answer Session

  Sunday, July 10, 2022
  2:15 PM – 2:25 PM

• OC 27.5 - Predictive performance of pharmacokinetic-guided prophylactic dosing of factor concentrates in hemophilia A and B (OPTI-CLOT TARGET study) – Preliminary results

  Sunday, July 10, 2022
  3:45 PM – 4:00 PM

• PB0212 - Collaboration between the World Federation of Hemophilia and National Registries for the Long-Term Follow-up of People with Hemophilia Treated with Gene Therapy

  Sunday, July 10, 2022
  6:30 PM – 7:30 PM

• OC 32.2 - Pleiotropic influence of rosuvastatin on apolipoproteins and their association with coagulation factor levels: results from the START trial

  Monday, July 11, 2022
  11:00 AM – 11:15 AM

• OC 47.2 - Prevalence and characteristics of non-neutralizing FVIII-specific antibodies in persons with hemophilia A – preliminary results

  Monday, July 11, 2022
  3:00 PM – 3:15 PM

• PB0652 - Transition readiness among Dutch adolescents and young adults with haemophilia: a questionnaire study

  Monday, July 11, 2022
  6:30 PM – 7:30 PM

• PB0797 - Restoration of VWF in Von Willebrand Disease type 3 canine ECFCs through CRISPR-Cas9 mediated gene editing

  Monday, July 11, 2022
  6:30 PM – 7:30 PM

• PB0805 - Development of Personalized CRISPR/Cas9 Based Gene Correction Therapy for Von Willebrand Disease

  Monday, July 11, 2022
  6:30 PM – 7:30 PM

• OC 53.1 - Studying VWF secretion under flow using microfluidics and patient-derived endothelial cells

  Tuesday, July 12, 2022
  10:45 AM – 11:00 AM

• OC 63.1 - Decreased thrombin generation profile is associated with severe bleeding phenotype in hemophilia: data from the Hemophilia in the Netherlands study

  Tuesday, July 12, 2022
  2:45 PM – 3:00 PM

• PB1156 - Desmopressin in hemophilia A carriers: determinants and duration of FVIII response

  Tuesday, July 12, 2022
  6:30 PM – 7:30 PM